DMH-1 (GMP)

DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons^[1][2]. In Vitro:DMH-1 (GMP) (0.5 μM) induces the formation of beating embryoid bodies (EBs), with an efficiency of approximately 20% on day 7, peaking at approximately 75% on day 9. Its efficiency at all evaluated time points is significantly higher than that of the DMSO control group^[1].
DMH-1 (GMP) (0.5 μM) specifically upregulates the expression profile of canonical cardiogenic genes, including BryT, Mesp1, Isl1 and Nkx2.5, and does not significantly induce the expression of non-cardiomyocyte mesodermal, endodermal or ectodermal markers compared with the DMSO control group^[1].
DMH-1 (GMP) (0.5 μM; 24-48 h) does not induce cell apoptosis^[1].
DMH-1 (GMP) (0.5-10 μM; 7 days) increases the expression of SOX1 in hiPSCs in a concentration-dependent manner^[2].
DMH-1 (GMP) (0.5 μM) induces hiPSC-derived neural progenitor cells to differentiate into β3-tubulin-positive neurons^[2].